BOMET-QoL-10 questionnaire for breast cancer patients with bone metastasis: the prospective MABOMET GEICAM study
-
Published:2019-12
Issue:1
Volume:3
Page:
-
ISSN:2509-8020
-
Container-title:Journal of Patient-Reported Outcomes
-
language:en
-
Short-container-title:J Patient Rep Outcomes
Author:
Barnadas A.ORCID, , Muñoz M., Margelí M., Chacón J. I., Cassinello J., Antolin S., Adrover E., Ramos M., Carrasco E., Jimeno M. A., Ojeda B., González X., González S., Constenla M., Florián J., Miguel A., Llombart A., Lluch A., Ruiz-Borrego M., Colomer R., Del Barco S.
Abstract
Abstract
Background
Bone metastasis (BM) is the most common site of disease in metastatic breast cancer (MBC) patients. BM impacts health-related quality of life (HRQoL). We tested prospectively the psychometric properties of the Bone Metastasis Quality of Life (BOMET-QoL-10) measure on MBC patients with BM.
Methods
Patients completed the BOMET-QoL-10 questionnaire, the Visual Analogue Scale (VAS) for pain, and a self-perceived health status item at baseline and at follow-up visits. We performed psychometric tests and calculated the effect size of specific BM treatment on patients´ HRQoL.
Results
Almost 70% of the 172 patients reported symptoms, 23.3% experienced irruptive pain, and over half were receiving chemotherapy. BOMET-QoL-10 proved to be a quick assessment tool performing well in readability and completion time (about 10 min) with 0–1.2% of missing/invalid data. Although BOMET-QoL-10 scores remained fairly stable during study visits, differences were observed for patient subgroups (e.g., with or without skeletal-related events or adverse effects). Scores were significantly correlated with physician-reported patient status, patient-reported pain, symptoms, and perceived health status. BOMET-QoL-10 scores also varied prospectively according to changes in pain intensity.
Conclusions
BOMET-QoL-10 performed well as a brief, easy-to-administer, useful, and sensitive HRQoL measure for potential use for clinical practice with MBC patients.
Trial registration
NCT03847220. Retrospectively registered on clinicaltrials.gov (February the 20th 2019).
Funder
Novartis Spain GEICAM Spanish Breast Cancer Group Roche Spain
Publisher
Springer Science and Business Media LLC
Subject
Health Information Management,Health Informatics
Reference34 articles.
1. Torre, L. A., Bray, F., Siegel, R. L., Ferlay, J., Lortet-Tieulent, J., & Jemal, A. (2015). Global cancer statistics, 2012. CA: a Cancer Journal for Clinicians, 65(2), 87–108. 2. Network MBC. 13 Facts About Metastatic Breast Cancer 2016 [Available from: http://www.mbcn.org/13-facts-about-metastatic-breast-cancer/. 3. Cardoso, F., Harbeck, N., Fallowfield, L., Kyriakides, S., Senkus, E., & Group EGW. (2012). Locally recurrent or metastatic breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 23(Suppl 7), vii11–vii19. 4. Yu, H. H., Tsai, Y. Y., & Hoffe, S. E. (2012). Overview of diagnosis and management of metastatic disease to bone. Cancer Control, 19(2), 84–91. 5. Hagberg, K. W., Taylor, A., Hernandez, R. K., & Jick, S. (2013). Incidence of bone metastases in breast cancer patients in the United Kingdom: Results of a multi-database linkage study using the general practice research database. Cancer Epidemiology, 37(3), 240–246.
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|